Bharat Immunologicals and Biologicals Corporation Limited Q1, Q2, Q3, Q4, FY 2016-17, FY 2015-16 Standalone / Consolidated Results, Revenues, Net Profit, Tax, EPS, Live Chart …

Bharat Immunologicals and Biologicals Corporation Limited Company Profile :

Bharat Immunologicals and Biologicals Corporation Limited is an Indian public sector biotechnology company.

The Company manufactures and produces a range of pharmaceuticals products, such as oral polio vaccines, zinc tablet and diarrhea management kit, among others. The Company’s segments include vaccine, which manufactures oral polio vaccines (trivalent oral polio vaccine (tOPV) and bivalent oral polio vaccine (bOPV)), and pharmaceutical, which manufactures and markets dispersible zinc tablet and diarrhea management kit.

BIBCOL is under the administrative control of the Department of Biotechnology, Ministry of Science and Technology.


Bharat Immunologicals & Biologicals Corporation ResultsBSE Code : 524663
NSE Symbol :
ISIN No. : INE994B01014
Industry : Pharmaceuticals
Face Value : Rs. 10.00


If you are an investor who has shares of Bharat Immunologicals & Biologicals Corporation or you are an stock market analyst then i am sure you might for Quarterly Results of Bharat Immunologicals & Biologicals Corporation.

In this article you will find Q1, Q2, Q3, Q4 and FY 2016-17 Results of Bharat Immunologicals & Biologicals Corporation. That’s not all, you can compare those results with previous year i.e., FY 2015-16 Results of Bharat Immunologicals & Biologicals Corporation.

Bharat Immunologicals & Biologicals Corporation Q1 Results 2016-17 :

Bharat Immunologicals & Biologicals Corporation will announce its Q1 FY 2016-17 Results in the month of July 2016. We will update the table below once the results are announced.

(Values in Cr.) Q1 Standalone Q1 Consolidated
Revenue  –
Other Income  –
Total Income  –
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Bharat Immunologicals & Biologicals Corporation will announce its Q2 FY 2016-17 Results in the month of October 2017.

(Values in Cr.) Q2 Standalone Q2 Consolidated
Revenue  –
Other Income  –
Total Income  –
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Bharat Immunologicals & Biologicals Corporation will announce its Q3 FY 2016-17 Results in the month of January 2017.

(Values in Cr.) Q3 Standalone Q3 Consolidated
Revenue  –
Other Income  –
Total Income  –
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Bharat Immunologicals & Biologicals Corporation will announce its Q4 FY 2016-17 Results in the month of April 2017.

(Values in Cr.) Q4 Standalone Q4 Consolidated
Revenue  –
Other Income  –
Total Income  –
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Bharat Immunologicals & Biologicals Corporation will announce its FY 2016-17 Results in the month of April 2017.

(Values in Cr.) FY 2016-17 Standalone FY 2016-17 Consolidated
Revenue  –
Other Income  –
Total Income  –
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Note : We will update the results table above as and when results are announced. Visit again.

Bharat Immunologicals & Biologicals Corporation Previous Year’s Results (FY 2015-16) :

(Values in Cr.) Standalone Consolidated
Revenue 128.03  –
Other Income 1.37  –
Total Income 129.40  –
Expenditure -133.95  –
Interest -2.38  –
Depreciation -0.65  –
PBT -7.58  –
Tax 2.23  –
Net Profit -5.35  –
Equity 43.18  –
EPS -1.24  –

Note : If you like this information about Bharat Immunologicals & Biologicals Corporation Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.